The rise of antifungal resistance: What it means for dermatology.

Sammer Murase*

Department of Dermatology, Swansea University, UK

Introduction

Antifungal resistance is an emerging concern in the medical field, and its impact on dermatology is becoming increasingly evident. As dermatologists continue to treat a wide variety of fungal infections, the rise of antifungal resistance poses a serious challenge to effective treatment. Fungal infections, which range from superficial conditions like athlete's foot and ringworm to more serious systemic infections, have traditionally been treated with antifungal medications. However, the growing resistance to these drugs is making it more difficult to manage common dermatological conditions. This article explores the causes, consequences, and potential strategies to address antifungal resistance in dermatology [1].

Antifungal resistance occurs when fungi evolve mechanisms that allow them to survive exposure to antifungal drugs that would typically kill or inhibit their growth. Just like bacteria, fungi can develop resistance through genetic mutations that enable them to neutralize or avoid the effects of antifungals. Over time, the widespread and often inappropriate use of antifungal treatments in both humans and animals has contributed to the acceleration of this resistance. In dermatology, antifungal drugs like terbinafine, ketoconazole, and fluconazole have been the cornerstone of treatment for many fungal skin infections. However, the increased resistance to these medications is making it harder to treat conditions effectively, especially when infections are persistent or recurrent [2].

Several factors contribute to the rise of antifungal resistance in dermatology. One of the most significant contributors is the overuse and misuse of antifungal medications. Many patients use antifungals without proper medical supervision, leading to incorrect dosing or duration of therapy. Additionally, self-medication, especially with over-the-counter antifungal creams or shampoos, can lead to suboptimal treatment regimens, giving fungi a chance to adapt and resist [3].

Another important factor is the use of antifungals in agriculture and animal husbandry. The widespread use of antifungal agents in livestock to prevent fungal infections or promote growth has led to the development of resistant strains that can be transmitted to humans through direct contact or consumption of contaminated animal products [4].

Fungal infections in immunocompromised individuals, such as those with HIV/AIDS, cancer, or those on immunosuppressive drugs, are also a major driver of resistance. These patients often require long-term or repeated antifungal treatments, which increases the risk of resistance developing [5].

The rise of antifungal resistance has significant implications for dermatology. Fungal infections, particularly superficial ones like tinea pedis (athlete's foot), tinea corporis (ringworm), and seborrheic dermatitis, are common conditions that dermatologists treat regularly. The effectiveness of traditional antifungal treatments is now being challenged, which may lead to longer treatment times, higher healthcare costs, and increased morbidity for patients [6].

In more severe cases, such as fungal infections that affect the nails (onychomycosis) or hair (tinea capitis), the development of resistance can lead to treatment failure. Patients may experience persistent symptoms, recurring infections, and a reduced quality of life. Furthermore, the lack of effective treatment options for resistant infections increases the risk of more severe complications, including secondary bacterial infections and the potential spread of the infection to other areas of the body [7].

One of the major challenges in managing antifungal resistance is the limited number of antifungal drugs available. Compared to antibiotics, the arsenal of antifungal agents is relatively small, and new antifungal drugs have been slow to emerge. This limitation means that when resistance occurs, dermatologists may have fewer options to treat infections effectively. Additionally, many of the antifungal agents that are available can have significant side effects, especially when used over extended periods [8].

Infections caused by resistant fungi often require higher doses of medication or prolonged therapy, which can increase the risk of adverse reactions. Some patients may also develop resistance to multiple classes of antifungal drugs, which complicates treatment further. The growing resistance to antifungal agents calls for innovative strategies in both prevention and treatment [9].

Accurate diagnosis is crucial when dealing with resistant fungal infections. Dermatologists must ensure that the infection is properly identified before starting treatment. This involves conducting thorough clinical assessments and, when necessary, laboratory testing, such as fungal cultures or PCR-based methods, to identify the specific type of fungus involved. By identifying the causative organism, dermatologists can choose the most appropriate antifungal treatment [10].

***Correspondence to:** Sammer Murase, Department of Dermatology, Swansea University, UK, E-mail: sammer.murase@swansea.ac.uk

***Received:** 1-May-2025, Manuscript No. aarcd-25-164967; **Editor assigned:** 5-May-2025, PreQC No. aarcd-25-164967 (PQ); **Reviewed:** 17-May-2025, QC No. aarcd-25-164967; **Revised**: 24-May-2025, Manuscript No. aarcd-25-164967 (R); **Published**: 31-May-2025, DOI:10.35841/aarcd-8.3.265.*

***Citation:** Murase S. The rise of antifungal resistance: What it means for dermatology. Res Clin Dermatol. 2025;8(3):265.*

Conclusion

The rise of antifungal resistance poses significant challenges for dermatology, particularly as common fungal infections become more difficult to treat. Overuse and misuse of antifungal medications, coupled with the slow development of new drugs, contribute to the growing problem of resistance. However, through judicious use of antifungals, improved diagnostic methods, patient education, and ongoing research, dermatologists can help mitigate the impact of antifungal resistance. The future of treating resistant fungal infections will rely on innovation, collaboration, and a comprehensive approach that includes both prevention and treatment. In addressing the rise of antifungal resistance, dermatologists play a key role in safeguarding the effectiveness of antifungal therapies for generations to come.

References

1. Pai V, Ganavalli A, Kikkeri NN. Antifungal resistance in dermatology. Indian J Dermatol. 2018;63(5):361-8.
2. Gupta AK, Renaud HJ, Quinlan EM, et al. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses. Am J Clin Dermatol. 2021;22(2):149-57.
3. McCormick TS, Ghannoum M. Time to think antifungal resistance increased antifungal resistance exacerbates the burden of fungal infections including resistant dermatomycoses. Pathog Immun. 202;8(2):158.
4. Sacheli R, Hayette MP. Antifungal resistance in dermatophytes: Genetic considerations, clinical presentations and alternative therapies. J Fungi. 2021;7(11):983.
5. Lockhart SR, Chowdhary A, Gold JA. The rapid emergence of antifungal-resistant human-pathogenic fungi. Nat Rev Microbiol. 2023;21(12):818-32.
6. Kruithoff C, Gamal A, McCormick TS, et al. Dermatophyte infections worldwide: Increase in incidence and associated antifungal resistance. Life. 2023;14(1):1.
7. Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008;166:369-83.
8. Ghannoum M. Azole resistance in dermatophytes: Prevalence and mechanism of action. J Am Podiatr Med Assoc. 2016;106(1):79-86.
9. Gupta AK, Venkataraman M. Antifungal resistance in superficial mycoses. J Dermatol Treat. 2022;33(4):1888-95.
10. Denning DW. Antifungal drug resistance: An update. Eur J Hosp Pharm. 2022;29(2):109-12.

Citation: *Murase S. The rise of antifungal resistance: What it means for dermatology. Res Clin Dermatol. 2025;8(3):265.*